Proteomic analysis of rat tibialis anterior muscles at different stages of experimental autoimmune myasthenia gravis

Journal of Neuroimmunology

Volumn 261, Issue 1-2, 2013, Pages 141-145

  Gomez, Alejandro M ^a   Vanheel, Annelies ^b   Losen, Mario ^a   Molenaar, Peter C ^a   De Baets, Marc H ^a,b   Noben, Jean Paul ^b   Hellings, Niels ^b   Martinez Martinez, Pilar ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

2D DIGE; Autoimmunity; Muscle proteomics; Myasthenia gravis

Indexed keywords

BETA ENOLASE; CARBONATE DEHYDRATASE III; ENOLASE; PYRUVATE KINASE; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; INCLUSION BODY MYOSITIS; MASS SPECTROMETRY; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RAT; TIBIALIS ANTERIOR MUSCLE; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

2D-DIGE; AUTOIMMUNITY; MUSCLE PROTEOMICS; MYASTHENIA GRAVIS;

ANIMALS; DISEASE PROGRESSION; FEMALE; MUSCLE, SKELETAL; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; PROTEOMICS; RATS; RATS, INBRED LEW;

EID: 84880845749     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.05.008     Document Type: Article

References (29)

1. Asher O., Fuchs S., Zuk D., Rapaport D., Buonanno A. Changes in the expression of mRNAs for myogenic factors and other muscle-specific proteins in experimental autoimmune myasthenia gravis. FEBS Lett. 1992, 299:15-18.
2. Coers C., Telerman-Toppet N. Morphological and histochemical changes of motor units in myasthenia. Ann. N. Y. Acad. Sci. 1976, 274:6-19.
3. Comi G.P., Fortunato F., Lucchiari S., Bordoni A., Prelle A., Jann S., Keller A., Ciscato P., Galbiati S., Chiveri L., Torrente Y., Scarlato G., Bresolin N. Beta-enolase deficiency, a new metabolic myopathy of distal glycolysis. Ann. Neurol. 2001, 50:202-207.
4. Conti-Fine B.M., Milani M., Kaminski H.J. Myasthenia gravis: past, present, and future. J. Clin. Invest. 2006, 116:2843-2854.
5. Du A.L., Ren H.M., Lu C.Z., Tu J.L., Xu C.F., Sun Y.A. Carbonic anhydrase III is insufficient in muscles of myasthenia gravis patients. Autoimmunity 2009, 42:209-215.
6. Gomez A.M., Van Den Broeck J., Vrolix K., Janssen S.P., Lemmens M.A., Van Der Esch E., Duimel H., Frederik P., Molenaar P.C., Martinez-Martinez P., De Baets M.H., Losen M. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity 2010, 43:353-370.
7. Gomez A.M., Vrolix K., Martinez-Martinez P., Molenaar P.C., Phernambucq M., van der Esch E., Duimel H., Verheyen F., Voll R.E., Manz R.A., De Baets M.H., Losen M. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J. Immunol. 2011, 186:2503-2513.
8. Guyon T., Levasseur P., Truffault F., Cottin C., Gaud C., Berrih-Aknin S. Regulation of acetylcholine receptor alpha subunit variants in human myasthenia gravis. Quantification of steady-state levels of messenger RNA in muscle biopsy using the polymerase chain reaction. J. Clin. Invest. 1994, 94:16-24.
9. Isfort R.J., Hinkle R.T., Jones M.B., Wang F., Greis K.D., Sun Y., Keough T.W., Anderson N.L., Sheldon R.J. Proteomic analysis of the atrophying rat soleus muscle following denervation. Electrophoresis 2000, 21:2228-2234.
10. Isfort R.J., Wang F., Greis K.D., Sun Y., Keough T.W., Bodine S.C., Anderson N.L. Proteomic analysis of rat soleus and tibialis anterior muscle following immobilization. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2002, 769:323-332.
11. Keller A., Rouzeau J.D., Farhadian F., Wisnewsky C., Marotte F., Lamande N., Samuel J.L., Schwartz K., Lazar M., Lucas M. Differential expression of alpha- and beta-enolase genes during rat heart development and hypertrophy. Am. J. Physiol. 1995, 269:H1843-H1851.
12. Li Z.B., Lehar M., Samlan R., Flint P.W. Proteomic analysis of rat laryngeal muscle following denervation. Proteomics 2005, 5:4764-4776.
13. Lilley K.S., Friedman D.B. All about DIGE: quantification technology for differential-display 2D-gel proteomics. Expert Rev. Proteomics 2004, 1:401-409.
14. Martignago S., Fanin M., Albertini E., Pegoraro E., Angelini C. Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR. Neuropathol. Appl. Neurobiol. 2009, 35:103-110.
15. Martinez-Martinez P., Losen M., Duimel H., Frederik P., Spaans F., Molenaar P., Vincent A., De Baets M.H. Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis. Am. J. Pathol. 2007, 170:644-657.
16. Merkulova T., Dehaupas M., Nevers M.C., Creminon C., Alameddine H., Keller A. Differential modulation of alpha, beta and gamma enolase isoforms in regenerating mouse skeletal muscle. Eur. J. Biochem. 2000, 267:3735-3743.
17. Ohlendieck K. Proteomic profiling of fast-to-slow muscle transitions during aging. Front. Physiol. 2011, 2:105.
18. Parker K.C., Kong S.W., Walsh R.J., Salajegheh M., Moghadaszadeh B., Amato A.A., Nazareno R., Lin Y.Y., Krastins B., Sarracino D.A., Beggs A.H., Pinkus J.L., Greenberg S.A. Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis. Muscle Nerve 2009, 39:739-753.
19. Raisanen S.R., Lehenkari P., Tasanen M., Rahkila P., Harkonen P.L., Vaananen H.K. Carbonic anhydrase III protects cells from hydrogen peroxide-induced apoptosis. FASEB J. 1999, 13:513-522.
20. Richman D.P. Antibodies to low density lipoprotein receptor-related protein 4 in seronegative myasthenia gravis. Arch. Neurol. 2012, 69:434-435.
21. Robert-Pachot M., Desbos A., Moreira A., Becchi M., Tebib J., Bonnin M., Aitsiselmi T., Bienvenu J., Fabien N. Carbonic anhydrase III: a new target for autoantibodies in autoimmune diseases. Autoimmunity 2007, 40:380-389.
22. Russell A.J., Hartman J.J., Hinken A.C., Muci A.R., Kawas R., Driscoll L., Godinez G., Lee K.H., Marquez D., Browne W.F.t, Chen M.M., Clarke D., Collibee S.E., Garard M., Hansen R., Jia Z., Lu P.P., Rodriguez H., Saikali K.G., Schaletzky J., Vijayakumar V., Albertus D.L., Claflin D.R., Morgans D.J., Morgan B.P., Malik F.I. Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat. Med. 2012, 18:452-455.
23. Santoni V., Molloy M., Rabilloud T. Membrane proteins and proteomics: un amour impossible?. Electrophoresis 2000, 21:1054-1070.
24. Shevchenko A., Wilm M., Vorm O., Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996, 68:850-858.
25. Silvestri N.J., Wolfe G.I. Myasthenia gravis. Semin. Neurol. 2012, 32:215-226.
26. Sizova D., Charbaut E., Delalande F., Poirier F., High A.A., Parker F., Van Dorsselaer A., Duchesne M., Diu-Hercend A. Proteomic analysis of brain tissue from an Alzheimer's disease mouse model by two-dimensional difference gel electrophoresis. Neurobiol. Aging 2007, 28:357-370.
27. Tan S., Tan H.T., Chung M.C. Membrane proteins and membrane proteomics. Proteomics 2008, 8:3924-3932.
28. Vanheel A., Daniels R., Plaisance S., Baeten K., Hendriks J.J., Leprince P., Dumont D., Robben J., Brone B., Stinissen P., Noben J.P., Hellings N. Identification of protein networks involved in the disease course of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. PLoS One 2012, 7:e35544.
29. Zamecnik J., Vesely D., Jakubicka B., Cibula A., Pitha J., Schutzner J., Mazanec R. Atrophy of type II fibres in myasthenia gravis muscle in thymectomized patients: steroid-induced change with prognostic impact. J. Cell. Mol. Med. 2009, 13:2008-2018.